Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNAseq analysis of lung treated with GLS1 inhibitor [scRNA-seq Lung_BPTES]

ABSTRACT: scRNAseq analysis of lung treated with GLS1 inhibitor [scRNA-seq Lung_BPTES]

PROVIDER: PRJNA1281109 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

scRNAseq analysis of lung treated with GLS1 inhibitor [scRNA-seq Lung_BPTES]

Project description:We employed the Chromium GEM-X single-cell RNA sequencing platform by 10x Genomics to investigate the effects of the GLS1 inhibitor, BPTES, on the lung single-cell transcriptome of 19- to 20-month-old wild-type male mice. Previous studies have identified GLS1 as a potential senolytic reagent capable of eliminating senescent cells. Our aim was to determine which cell populations are selectively removed by GLS1 inhibition in aged mice and to assess how this intervention alters intercellular interactions across different cell types.

2025-07-02 | GSE300532 | GEO

scRNAseq analysis of kidney treated with GLS1 inhibitor [scRNA-seq Kid_BPTES]

Project description:scRNAseq analysis of kidney treated with GLS1 inhibitor [scRNA-seq Kid_BPTES]

| PRJNA1284762 | ENA

scRNAseq analysis of kidney treated with GLS1 inhibitor [scRNA-seq Kid_BPTES]

Project description:We employed the Chromium GEM-X single-cell RNA sequencing platform by 10x Genomics to investigate the effects of the GLS1 inhibitor, BPTES, on the kidney single-cell transcriptome of 19- to 20-month-old wild-type male mice. Previous studies have identified GLS1 as a potential senolytic reagent capable of eliminating senescent cells. Our aim was to determine which cell populations are selectively removed by GLS1 inhibition in aged mice and to assess how this intervention alters intercellular interactions across different cell types.

2025-07-02 | GSE301292 | GEO

GLS1 governs vascular smooth muscle cell phenotypic switching and aortic dissection via glutamate metabolism

Project description:To evaluate the roles of glutaminase 1 (GLS1) in vascular smooth muscle cells (VSMCs) phenotypic switching and aortic dissection (AD). Integrative transcriptomic analyses were performed to identify the candidate genes involved in VSMC phenotypic switching in AD. The expression of GLS1 in VSMCs was assessed by qRT-PCR, Western blot and immunofluorescence. RNA-sequencing analysis was performed to recapitulate possible changes in the transcriptome profile of GLS1 in VSMCs. We identified GLS1 as a potential regulator in AD. GLS1 expression was significantly downregulated in VSMCs from both human AD aortic tissues and mouse models. Mechanistically, down-regulation of GLS1 impaired glutamate metabolism, leading to reduced levels of glutathione and α-ketoglutarate, thereby promoting mitochondrial dysfunction and accumulation of reactive oxygen species, which activated the PI3K/AKT pathway and ultimately triggered VSMC phenotypic switching. These findings revealed a critical role of GLS1-mediated glutamate metabolism in VSMC phenotypic switching and suggest a promising therapeutic target for AD.

2026-03-20 | GSE324926 | GEO

GLS1 interactome in liver cells by IP followed by LC-MS/MS

Project description:Glutaminase (GLS1) is involved in the development of Alcoholic liver disease (ALD). Protein-protein interactions underlie the biological processes impacted by GLS1. we used immunoprecipitation-mass spectrometry (IP-MS) technology and found the proteins interacted with GLS1.

2025-12-08 | PXD050603 | Pride

scRNAseq analysis of lung with eliminating p16h cells [scRNA-seq Lung_DTR]

Project description:scRNAseq analysis of lung with eliminating p16h cells [scRNA-seq Lung_DTR]

| PRJNA1281112 | ENA

scRNAseq MS023-treated MuSCs

Project description:scRNAseq MS023-treated MuSCs

| PRJNA819980 | ENA

scRNAseq MS023-treated MuSCs

Project description:scRNAseq of MS023-treated muscle stem cells.

2023-01-05 | GSE199420 | GEO

scRNA-Seq of MC38 CD45+ Cells treated with EZH2 inhibitor PF-06821497

Project description:The purpose of this study was to determine the effect of EZH2 inhibitor (EZH2i) PF-06821497 on CD45+ cells isolated from MC38 tumors at day 17 post implantation. Mice were either treated for 7 days prior to endpoint or 16 days prior to endpoint with the EZH2i or with vehicle control. CD45+ cells were isolated and scRNA-Seq was performed on cells

2021-11-10 | GSE188473 | GEO

scRNAseq characterization of synovial stromal cells in mouse STIA

Project description:Objective: Upregulation of glycolysis and glutaminolysis in the rheumatoid arthritis fibroblast-like synoviocytes (RAFLS) has already been established by existing literature . Henceforth, this study was undertaken to determine if dual inhibition of these processes by novel phytobiologic c28MS have the potential of promising synergistic therapy for rheumatoid arthritis by targeting the underlying metabolic reprogramming as existing treatment strategies for RA do not target dual inhibition. Methods: Gene associations with HK2 and GLS expression were identified by examining murine and human available scRNA-seq. The metabolic profile of FLS cells was determined by 1H magnetic resonance spectroscopy under conditions of glycolytic and glutaminolysis inhibition and HK2 and GLS1 expression was evaluated by western blot. FLS functional analysis was conducted under similar inhibitory conditions. ELISA was employed for the quantification of pivotal markers namely IL6, CCL2 and MMP3. For arthritis experiments, mice were injected with K/BxN sera on Day 0 and treated for 10 days. Results: scRNAseq data identified... Metabolomic and functional analysis revealed that c28MS had the potential of checking the aggressive behavior of RAFLS by targeting upregulated glycolysis and glutaminolysis thereby inhibiting them. Target expression remained unaffected by the action of the dual inhibitor suggesting only potential blockage. Furthermore, the compound was able to inhibit inflammatory arthritis by decreasing the clinical score and paw inflammation in the K/BxN model. Conclusion: Our findings imply that dual inhibition of glycolysis and glutaminolysis could be an effective strategy in the treatment of RA with chances of greater remission. It also suggests that targeting more than one pathway in the metabolome can be a novel treatment approach in non-cancer scenarios.

2023-04-20 | GSE230145 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data